ORAMED PHARMACEUTICALS ENTERS MATERIAL DEFINITIVE AGREEMENT
Ticker: ORMP · Form: 8-K · Filed: Jan 23, 2024 · CIK: 1176309
| Field | Detail |
|---|---|
| Company | Oramed Pharmaceuticals Inc. (ORMP) |
| Form Type | 8-K |
| Filed Date | Jan 23, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.012, $70 million, $20 million, $10 million, $20 m |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-action
TL;DR
**ORMP just signed a big deal, could be a game-changer.**
AI Summary
Oramed Pharmaceuticals Inc. (ORMP) filed an 8-K on January 23, 2024, reporting a material definitive agreement entered into on January 22, 2024. This filing indicates a significant corporate action, likely a new contract or partnership, which could impact the company's future operations and financial performance. For investors, this matters because such agreements can signal new revenue streams, strategic shifts, or increased operational costs, directly influencing the stock's valuation and future prospects.
Why It Matters
This filing signals a new, potentially impactful business arrangement for Oramed, which could lead to new opportunities or obligations that affect its financial health and stock price.
Risk Assessment
Risk Level: medium — The filing indicates a material agreement but lacks specific details, creating uncertainty about its financial implications and potential risks or benefits.
Analyst Insight
Investors should monitor Oramed's future announcements for specific details regarding the 'Material Definitive Agreement' to assess its potential impact on the company's financials and strategic direction before making investment decisions.
Key Numbers
- $0.012 — par value per share (par value of Oramed's Common Stock)
Key Players & Entities
- Oramed Pharmaceuticals Inc. (company) — the registrant filing the 8-K
- 001-35813 (dollar_amount) — Commission File Number
- January 22, 2024 (date) — date of earliest event reported
- January 23, 2024 (date) — date of 8-K filing
- ORMP (company) — trading symbol for Oramed Pharmaceuticals Inc.
- The Nasdaq Capital Market (company) — exchange where Oramed's common stock is registered
- Tel Aviv Stock Exchange (company) — exchange where Oramed's common stock is registered
Forward-Looking Statements
- Oramed will release further details about the 'Material Definitive Agreement' in a subsequent filing or press release. (Oramed Pharmaceuticals Inc.) — high confidence, target: Q1 2024
FAQ
What is the specific nature of the 'Material Definitive Agreement' Oramed Pharmaceuticals Inc. entered into?
The filing states that Oramed Pharmaceuticals Inc. entered into a 'Material Definitive Agreement' on January 22, 2024, but it does not provide specific details about the nature of this agreement, such as the parties involved, the terms, or the financial implications.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 22, 2024, which is the date Oramed Pharmaceuticals Inc. entered into the Material Definitive Agreement.
On which stock exchanges is Oramed Pharmaceuticals Inc.'s Common Stock registered?
Oramed Pharmaceuticals Inc.'s Common Stock, with a par value of $0.012, is registered on The Nasdaq Capital Market and the Tel Aviv Stock Exchange under the trading symbol ORMP.
What is the business address and phone number of Oramed Pharmaceuticals Inc. as listed in the filing?
The business address of Oramed Pharmaceuticals Inc. is 1185 Avenue of the Americas, Third Floor, New York, New York 10036, and its telephone number is 844-967-2633.
What is the Commission File Number for Oramed Pharmaceuticals Inc.?
The Commission File Number for Oramed Pharmaceuticals Inc. is 001-35813.
Filing Stats: 1,318 words · 5 min read · ~4 pages · Grade level 14.9 · Accepted 2024-01-23 16:45:15
Key Financial Figures
- $0.012 — ch registered Common Stock, par value $0.012 ORMP The Nasdaq Capital Market, T
- $70 million — Oramed. HTIT will contribute to the JV $70 million in cash, while Oramed will contribute $
- $20 million — n in cash, while Oramed will contribute $20 million (comprised of $10 million in cash and $
- $10 million — ll contribute $20 million (comprised of $10 million in cash and $10 million in shares of Or
- $20 m — nto the JV up to an aggregate amount of $20 million, thereby increasing its equity ho
Filing Documents
- ea192032-8k_oramed.htm (8-K) — 44KB
- ea192032ex10-1_oramed.htm (EX-10.1) — 428KB
- ex10-1_001.jpg (GRAPHIC) — 68KB
- 0001213900-24-005780.txt ( ) — 815KB
- ormp-20240122.xsd (EX-101.SCH) — 3KB
- ormp-20240122_lab.xml (EX-101.LAB) — 33KB
- ormp-20240122_pre.xml (EX-101.PRE) — 22KB
- ea192032-8k_oramed_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORAMED PHARMACEUTICALS INC. By: /s/ Nadav Kidron Name: Nadav Kidron Title: President and CEO January 23, 2024 3